Travis Steed
Stock Analyst at Barclays
(2.69)
# 2,127
Out of 4,996 analysts
86
Total ratings
64.29%
Success rate
15.32%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $184.60 | +41.39% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $253.37 | +26.30% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $133.55 | +12.32% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $71.37 | +19.10% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $76.25 | +18.03% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $11.37 | +181.44% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $21.98 | +104.73% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $14.48 | +210.77% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $369.02 | -14.64% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $318.00 | -7.23% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $17.16 | -6.76% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $12.00 | +175.00% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $98.24 | +62.87% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $441.12 | -28.59% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.74 | +359.77% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $13.90 | +79.86% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.90 | +470.47% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $67.10 | +86.29% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $94.22 | +53.90% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $98.18 | -48.05% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $46.00 | +280.43% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.20 | +309.09% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $50.61 | -56.53% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $184.60
Upside: +41.39%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $253.37
Upside: +26.30%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $133.55
Upside: +12.32%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $71.37
Upside: +19.10%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $76.25
Upside: +18.03%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $11.37
Upside: +181.44%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $21.98
Upside: +104.73%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $14.48
Upside: +210.77%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $369.02
Upside: -14.64%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $318.00
Upside: -7.23%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $17.16
Upside: -6.76%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $12.00
Upside: +175.00%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $98.24
Upside: +62.87%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $441.12
Upside: -28.59%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.74
Upside: +359.77%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $13.90
Upside: +79.86%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.90
Upside: +470.47%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $67.10
Upside: +86.29%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $94.22
Upside: +53.90%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $98.18
Upside: -48.05%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $46.00
Upside: +280.43%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.20
Upside: +309.09%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $50.61
Upside: -56.53%